Medicina
Departamento
Instituto de Investigación Sanitaria La Fe
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria La Fe (390)
2024
-
ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy: the Spanish registry
Blood
-
Diagnóstico y tratamiento de los trastornos de la presión intracraneal: Documento de consenso del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología
Neurologia
-
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
International Journal of Dermatology
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
Hepatology, Vol. 77, Núm. 4, pp. 1095-1105
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
International Journal of Dermatology
-
Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain
Journal of Clinical Medicine, Vol. 12, Núm. 16
-
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission
British Journal of Haematology, Vol. 201, Núm. 6, pp. 1169-1178
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Journal of the European Academy of Dermatology and Venereology
2022
-
CfDNA Measurement as a Diagnostic Tool for the Detection of Brain Somatic Mutations in Refractory Epilepsy
International Journal of Molecular Sciences, Vol. 23, Núm. 9
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Clinical, histological, and genetic features of 25 patients with autosomal dominant progressive external ophthalmoplegia (Ad-PEO)/PEO-plus due to TWNK mutations
Journal of Clinical Medicine, Vol. 11, Núm. 1
-
Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation
Transplantation, Vol. 106, Núm. 6, pp. 1123-1131
-
Decalogue for the selection of oral antibiotics for lower respiratory tract infections
Revista Espanola de Quimioterapia, Vol. 35, Núm. 1, pp. 16-29
-
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Dermatologic Therapy, Vol. 35, Núm. 2
-
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting
Dermatologic Therapy, Vol. 35, Núm. 8
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23